Halozyme Therapeutics, Inc. (FRA:RV7)

Market Cap	7.11B +1.0%
Revenue (ttm)	1.19B +37.6%
Net Income	269.89M -28.6%
EPS	2.18 -25.4%
Shares Out	n/a
PE Ratio	26.34
Forward PE	8.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	135
Open	60.96
Previous Close	62.14
Day's Range	60.96 - 60.96
52-Week Range	42.45 - 68.84
Beta	n/a
RSI	44.59
Earnings Date	Feb 17, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 423
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RV7

Financial Performance

In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.

Financial numbers in USD